Alper, K. R. Chapter 1 Ibogaine: A review. in The Alkaloids: Chemistry and Biology 1–38 (Elsevier). https://doi.org/10.1016/s0099-9598(01)56005-8 (2001).
Cherian, K. N. et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nat. Med. 30, 373–381 (2024).
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P. & Amoroso, T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress 4, 247054702093956 (2020).
Noller, G. E., Frampton, C. M. & Yazar-Klosinski, B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am. J. Drug Alcohol Abus. 44, 37–46 (2018).
Mosca, A. et al. Ibogaine/noribogaine in the treatment of substance use disorders: A systematic review of the current literature. Curr. Neuropharmacol. 21, 2178–2194 (2023).
Yaden, D. B. & Griffiths, R. R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 4, 568–572 (2021).
Brown, R. et al. 431. Higher intensity of mystical experience following magnesium-ibogaine is associated with larger decreases in PTSD severity. Biol. Psychiatry 97, S274–S275 (2025).
Ko, K., Knight, G., Rucker, J. J. & Cleare, A. J. Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front. Psychiatry 13, 917199 (2022).
Helsley, S., Fiorella, D., Rabin, R. A. & Winter, J. C. Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. Pharmacol. Biochem. Behav. 59, 419–425 (1998).
Brown, T. K., Noller, G. E. & Denenberg, J. O. Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorder. J. Psychoact. Drugs 51, 155–165 (2019).
Schenberg, E. E. et al. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. https://doi.org/10.1556/2054.01.2017.007 (2017).
Marton, S. et al. Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Front. Pharmacol. 10, 193 (2019).
Wasko, M. J., Witt-Enderby, P. A. & Surratt, C. K. DARK classics in chemical neuroscience: Ibogaine. ACS Chem. Neurosci. 9, 2475–2483 (2018).
Rodríguez-Cano, B. J. et al. Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences. Drug Alcohol Rev. 42, 401–414 (2023).
Davis, A. K., Renn, E., Windham-Herman, A.-M., Polanco, M. & Barsuglia, J. P. A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification. J. Psychoact. Drugs 50, 287–297 (2018).
Kohek, M., Ohren, M., Hornby, P., Alcázar-Córcoles, M. Á & Bouso, J. C. The ibogaine experience: A qualitative study on the acute subjective effects of ibogaine. Anthropol. Conscious. 31, 91–119 (2020).
Rodger, J. Understanding the healing potential of ibogaine through a comparative and interpretive phenomenology of the visionary experience. Anthropol. Conscious. 29, 77–119 (2018).
Inc, V. T. Constructing Grounded Theory 2nd edition | 9780857029140, 9781446293492. VitalSource https://www.vitalsource.com/products/constructing-grounded-theory-kathy-charmaz-v9781446293492.
Charmaz, K. The power of constructivist grounded theory for critical inquiry. Qual. Inq. 23, 34–45 (2017).
Harris, P. A. et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
Qualitative Data Analysis Learning Center — Delve. https://delvetool.com/learn.
González, J. et al. EEG gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine in the rat. ACS Pharmacol. Transl. Sci. 4, 517–525 (2021).
Hack, L. M. et al. Reduction in trauma-related symptoms after anesthetic-induced intra-operative dreaming. Am. J. Psychiatry 181, 563–564 (2024).
Hudachek, L. & Wamsley, E. J. A meta-analysis of the relation between dream content and memory consolidation. Sleep 46, zsad111 (2023).
Hipólito, I., Mago, J., Rosas, F. & Carhart-Harris, R. Pattern breaking: a complex systems approach to psychedelic medicine. Neurosci. Conscious. 2023, niad017 (2023).
McNamara, P. & Grafman, J. Psychedelics and Supernatural Agents: The Role of REM Physiology. in The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences (eds Yaden, D. & van Elk, M.) 0 (Oxford University Press). https://doi.org/10.1093/oxfordhb/9780192844064.013.24.
Koslowski, M., de Haas, M.-P. & Fischmann, T. Converging theories on dreaming: Between Freud, predictive processing, and psychedelic research. Front. Hum. Neurosci 17, 1080177 (2023).
Noorani, T. & Alderson-Day, B. Spotlight commentary: REBUS and the anarchic brain. Neurosci. Conscious. 2020, niaa007 (2020).
Safron, A., Juliani, A., Reggente, N., Klimaj, V. & Johnson, M. On the varieties of conscious experiences: Altered beliefs under psychedelics (ALBUS). Neurosci. Conscious. 2025, niae038 (2025).
Pezzulo, G., Zorzi, M. & Corbetta, M. The secret life of predictive brains: what’s spontaneous activity for? Trends Cogn. Sci. 25, 730–743 (2020).
Carhart-Harris, R. L. & Friston, K. J. REBUS and the Anarchic Brain: Toward a unified model of the brain action of psychedelicss. Pharmacol. Rev. 71, 316–344 (2019).
Glick, S. D., Maisonneuve, I. M. & Pearl, S. M. Evidence for roles of κ-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 749, 340–343 (1997).
Doss, M. K. et al. The acute effects of the atypical dissociative hallucinogen salvinorin A on functional connectivity in the human brain. Sci. Rep. 10, 16392 (2020).
Shedler, J. The efficacy of psychodynamic psychotherapy. Am. Psychol. 65, 98–109 (2010).
Chessick, R. D. The Future of Psychoanalysis. (State University of New York Press, 2012).
Treatment (US), C. for S. A. Exhibit 1.3-4. DSM-5 Diagnostic Criteria for PTSD. https://www.ncbi.nlm.nih.gov/books/NBK207191/ (2014).
Farrants, J. The ‘false memory’ debate: A critical review of the research on recovered memories of child… Couns. Psychol. Q. 11, 229 (19980901).
Freud, S. The Ego and the Id. (Courier Dover Publications, 2018).
Freud, A. The Ego and the Mechanisms of Defense (1967).
Carhart-Harris, R. L. et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front. Hum. Neurosci. 8, 20 (2014).
Császár-Nagy, N., Kapócs, G. & Bókkon, I. Classic psychedelics: The special role of the visual system. Rev. Neurosci. 30, 651–669 (2019).
Merchant, J. Analytical Theory (Jung). in Encyclopedia of Personality and Individual Differences 148–153 (Springer, Cham, 2020). https://doi.org/10.1007/978-3-319-24612-3_1360.
Pietikainen, P. Archetypes as symbolic forms. J. Anal. Psychol. 43, 325–343 (1998).
DeMarree, K. G., Naragon-Gainey, K. & Giancola, A. Validation of different forms of present-moment awareness using cognitive and behavioral outcomes. Psychol. Assess. 35, 572–581 (2023).
Self-as-Context | The Oxford Handbook of Acceptance and Commitment Therapy | Oxford Academic. https://academic.oup.com/edited-volume/38851/chapter-abstract/337814775?redirectedFrom=fulltext.
Spiegel, D. Hypnosis, dissociation and trauma. Int. Handb. Clin. Hypn. 143–158 (2001).
Polito, V., Barnier, A. J. & Woody, E. Z. Developing the sense of agency rating scale (SOARS): An empirical measure of agency disruption in hypnosis. Conscious. Cogn. 22, 684–696 (2013).
Terhune, D. B., Cleeremans, A., Raz, A. & Lynn, S. J. Hypnosis and top-down regulation of consciousness. Neurosci. Biobehav. Rev. 81, 59–74 (2017).
Jiang, H., White, M. P., Greicius, M. D., Waelde, L. C. & Spiegel, D. Brain activity and functional connectivity associated with hypnosis. Cereb. Cortex N. Y. N. 1991 27, 4083–4093 (2017).
Spiegel, D. Tranceformation: Digital dissemination of hypnosis. Neuron 112, 340–341 (2024).
Bedi, G., Phan, K. L., Angstadt, M. & de Wit, H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacol. (Berl.) 207, 73–83 (2009).
Durand, F., Isaac, C. & Januel, D. Emotional memory in post-traumatic stress disorder: A systematic PRISMA review of controlled studies. Front. Psychol. 10, 303 (2019).
Chen, K., Kokate, T. G., Donevan, S. D., Carroll, F. I. & Rogawski, M. A. Ibogaine block of the NMDA receptor: In vitro and in vivo studies. Neuropharmacology 35, 423–431 (1996).
Curran, H. V. & Morgan, C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95, 575–590 (2000).
Stoliker, D., Egan, G. F. & Razi, A. Reduced precision underwrites ego dissolution and therapeutic outcomes under psychedelics. Front. Neurosci 16, 827400 (2022).
Chen, Z. J. Psychology of mysticism: Toward a layered hierarchy model. Arch. Psychol. Relig. 46, 286–298 (2024).
Orlowski, P. et al. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. J Psychopharmacol 36, 987–1000 (2021).
Yaden, D. B., Haidt, J., HoodJr, R. W., Vago, D. R. & Newberg, A. B. The varieties of self-transcendent experience. Rev. Gen. Psychol. 21, 143–160 (2017).
Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol. Ther. 197, 83–102 (2019).
Benevides, B. G. WILLIAM JAMES and the role of mysticism in religion. Manuscrito 44, 453–488 (2021).
Maslow, A. H. Toward a Psychology of Being. (Princeton, N.J. : Van Nostrand, 1968).
Hoffman, E. & Muramoto, S. Peak-experiences among Japanese youth. J. Humanist. Psychol. 47, 524–540 (2007).
Marshall, M. Logotherapy Revisited: Review of the Tenets of Viktor E. Frankl’s Logotherapy. (Createspace Independent Publishing Platform, 2012).
Vos, J., Craig, M. & Cooper, M. Existential therapies: A meta-analysis of their effects on psychological outcomes. J. Consult. Clin. Psychol. 83, 115–128 (2015).
MDMA enhances emotional empathy and prosocial behavior | Social Cognitive and Affective Neuroscience | Oxford Academic. https://academic.oup.com/scan/article/9/11/1645/1681238.
Rogers, C. R. Client-Centered Therapy, Its Current Practice, Implications, and Theory. (Houghton Mifflin Harcourt (HMH), 1951).
Elliott, R., Bohart, A. C., Watson, J. C. & Murphy, D. Therapist empathy and client outcome: An updated meta-analysis. Psychotherapy 55, 399–410 (2018).
Bateman, A. W. & Fonagy, P. Mentalization-Based Treatment of BPD. J. Personal. Disord. 18, 36–51 (2004).
Beck, J. S. Cognitive Behavior Therapy, Second Edition: Basics and Beyond. (Guilford Press, 2011).
Foa, E. B. & Kozak, M. J. Emotional processing of fear: Exposure to corrective information. Psychol. Bull. 99, 20–35 (1986).
Cuijpers, P. et al. Cognitive behavior therapy for mental disorders in adults: A unified series of meta-analyses. JAMA Psychiatry https://doi.org/10.1001/jamapsychiatry.2025.0482 (2025).
Baumann, M. H., Rothman, R. B., Pablo, J. P. & Mash, D. C. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J. Pharmacol. Exp. Ther. 297, 531–539 (2001).
Hjorth, O. R. et al. Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: A randomized clinical trial. Transl. Psychiatry 11, 1–8 (2021).
Hai, A., Cai, L. X., Lee, T., Lelyveld, V. S. & Jasanoff, A. Molecular fMRI of serotonin transport. Neuron 92, 754–765 (2016).
Dunlap, L. E., Andrews, A. M. & Olson, D. E. Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine. ACS Chem. Neurosci. 9, 2408–2427 (2018).
Glick, S. D., Maisonneuve, I. M. & Szumlinski, K. K. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem. Biol. 56, 39–53 (2001).
Jørgensen, H., Kjær, A., Knigge, U., Møller, M. & Warberg, J. Serotonin stimulates hypothalamic mRNA expression and local release of neurohypophysial peptides. J. Neuroendocrinol. 15, 564–571 (2003).
Algoe, S. B., Kurtz, L. E. & Grewen, K. Oxytocin and social bonds: The role of oxytocin in perceptions of romantic partners’ bonding behavior. Psychol. Sci. 28, 1763–1772 (2017).
Osmond, H. A review of the clinical effects of psychotomimetic agents. Ann. N. Y. Acad. Sci. 66, 418–434 (1957).
Source link
FEB
2026